QT interval prolongation: and the beat goes on.

Area of Science:

• Cardiovascular Pharmacology
• Computational Toxicology

Background:

• QT interval prolongation is a critical safety concern for new bioactive agents.
• The human Ether-à-go-go-Related Gene (hERG) channel is central to cardiac repolarization and action potential duration.
• Understanding factors influencing QT prolongation is essential for drug development.

Purpose of the Study:

• To provide an overview of the hERG channel and its role in QT prolongation.
• To review fundamental cardiac electrophysiology, action potentials, and pre-clinical assays.
• To introduce in silico methods for predicting hERG channel blockers and discuss their strengths and weaknesses.

Main Methods:

• Review of cardiac electrophysiology and action potential basics.
• Discussion of pre-clinical assays for assessing hERG channel activity.
• Introduction to in silico modeling approaches for predicting hERG blockers.

Main Results:

• The hERG channel's critical role in cardiac repolarization is highlighted.
• Various factors contributing to QT interval prolongation risk are identified.
• The current landscape of in silico prediction methods for hERG blockers is presented.

Conclusions:

• A comprehensive understanding of hERG channel function is vital for drug safety assessment.
• In silico models offer valuable tools for predicting potential hERG blockers, but require careful application.
• Integrating electrophysiology, pre-clinical assays, and computational modeling enhances the evaluation of drug-induced QT prolongation risk.